Live Chat ×
Skip to main content

May Event: Scoring PD-L1 in Triple Negative Breast Cancer using the FDA-approved Ventana PD-L1 (SP142) IHC assay

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Moderator - Dr. Denise Croix

    Dr. Denise Croix is a Scientific Affairs Manager at Roche Diagnostics Corporation.

  • Dr. Michael Lynch

    Dr. Lynch is a Pathologist working with the North America Medical and Scientific Affairs field team that is dedicated to IHC diagnostic assay SP142 (PD-L1). He has been serving in this role since May of 2016. Before taking this role, he was the Lead Pathologist for Ventana Medical Systems’ HE 600 platform serving in that role for approximately 4 years.
    He joined Ventana in 2012 after working for 20 years in private practice assuming a variety of different roles including acting as the medical director of laboratories and chairman of the tumor boards, and sitting on medical advisory boards.
    Dr. Lynch received his MD from the University of Utah, subsequently carrying out a residency in anatomic and clinical pathology at the University of Vermont. During residency, he served as an officer in the ASCP resident physician’s section and is now a fellow of the College of American Pathology. He has published multiple abstracts and articles in the professional press primarily in the areas of vitamin K metabolism and prostacyclin production. He has broad experience in all areas of anatomic pathology including H&E, special stains, and immunohistochemistry.

  • Dr. Bharathi Vennapusa

    Dr. Vennapusa is a Pathologist working with the North America Medical and Scientific Affairs field team that is dedicated to IHC companion diagnostic assay SP142 (PD-L1). She has been serving in this role since July of 2018. Before taking this role, she worked at Ventana Medical Systems in different roles as Staff Pathologist, CAP/CLIA Laboratory Medical Director and Director of CDx Clinical Operations. She was the Lead Pathologist for SP142 CDx development franchise since the initiation in 2012 until marketing of UC and NSCLC indications. She also worked on RCC and TNBC indications as the franchise lead pathologist. She joined Ventana in 2011 after completing her fellowship training in molecular genetic pathology.
    Dr Vennapusa completed her medical school at Kurnool Medical College in India and did residency and practiced as a General Surgeon in India. After moving to the United States, she did a research fellowship at Temple University in Molecular Pathology, and ventured into doing residency in anatomic and clinical pathology at the University of New Mexico. During residency she worked with different molecular techniques, including NGS. She proceeded to do her fellowship training in molecular genetic pathology (MGP) at the University of Pittsburgh Medical Center. She is board certified in anatomic, clinical and molecular pathology. She has published multiple abstracts and articles and is an inventor. She has broad experience in IHC CDx development under design control, clinical trials, Pre-sub and PMA submissions, FDA and EU regulatory authority interactions, prototype IHC development, CAP accreditation and CLIA certification. 

  • Moderator - Dr. Alex Chang

    Dr. Alex Chang is a Scientific Affairs Manager at Roche Diagnostics Corporation.

May 6, 2020
Wed 12:00 PM EDT

Duration 1H 30M

This live web event has ended.